ACI
ALNY icon

AMP Capital Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

AMP Capital Investors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,424
Closed -$4.8M – 230
2021
Q3 		$4.8M Sell
25,424
-3,684
-13% -$691K 0.03% 557
2021
Q2 		$4.92M Hold
29,108
– – 0.02% 607
2021
Q1 		$4.09M Sell
29,108
-259
-0.9% -$39K 0.02% 650
2020
Q4 		$3.85M Sell
29,367
-2,166
-7% -$289K 0.02% 645
2020
Q3 		$4.57M Buy
31,533
+136
+0.4% +$19.3K 0.03% 553
2020
Q2 		$4.64M Sell
31,397
-155
-0.5% -$20.9K 0.03% 524
2020
Q1 		$3.43M Hold
31,552
– – 0.03% 558
2019
Q4 		$3.62M Buy
31,552
+5,495
+21% +$548K 0.02% 644
2019
Q3 		$2.11M Sell
26,057
-376
-1% -$29.7K 0.01% 741
2019
Q2 		$1.88M Hold
26,433
– – 0.01% 767
2019
Q1 		$2.39M Sell
26,433
-1,193
-4% -$99.8K 0.01% 715
2018
Q4 		$1.94M Sell
27,626
-102
-0.4% -$7.84K 0.01% 728
2018
Q3 		$2.5M Sell
27,728
-8,700
-24% -$875K 0.01% 711
2018
Q2 		$3.59M Sell
36,428
-2,300
-6% -$228K 0.02% 619
2018
Q1 		$5.03M Buy
38,728
+11,693
+43% +$1.51M 0.03% 534
2017
Q4 		$3.43M Buy
+27,035
New +$3.4M 0.02% 645
2016
Q4 		– Sell
-19,559
Closed -$1.37M – 1209
2016
Q3 		$1.37M Hold
19,559
– – 0.01% 805
2016
Q2 		$1.09M Hold
19,559
– – 0.01% 827
2016
Q1 		$1.16M Sell
19,559
-100
-0.5% -$6.65K 0.01% 809
2015
Q4 		$1.86M Sell
19,659
-9,353
-32% -$867K 0.01% 733
2015
Q3 		$2.24M Buy
29,012
+9,953
+52% +$1.11M 0.02% 659
2015
Q2 		$2.18M Buy
+19,059
New +$2.28M 0.01% 694

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

AMP Capital Investors's ALNY Position: Q4 2021 in Review

AMP Capital Investors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2021, closing a stake of 25,424 shares — an estimated $4.8M sold.

AMP Capital Investors first reported a position in ALNY in Q2 2015 and held it in 22 quarters. The position peaked at $5.03M in Q1 2018. 434 funds tracked by Wall St. Rank hold ALNY as of Q4 2021.

  • AMP Capital Investors reported no remaining Alnylam Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • AMP Capital Investors sold 25,424 Alnylam Pharmaceuticals shares in Q4 2021, an estimated $4.8M.
  • AMP Capital Investors first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 22 quarters.
  • AMP Capital Investors's Alnylam Pharmaceuticals position peaked at $5.03M in Q1 2018.
  • 434 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2021.

Based on AMP Capital Investors's 13F filing for Q4 2021, filed 14 Feb 2022.